Literature DB >> 20182352

Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension.

Chieh L Wong1, Richard Szydlo, Simon Gibbs, Mike Laffan.   

Abstract

The role of thrombosis and hereditary thrombotic risk factors in the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) and non-CTEPH is not clear. We retrospectively analyzed the frequency of hereditary and acquired thrombotic risk factors in 245 patients with pulmonary hypertension, of whom 45 had CTEPH and 200 had non-CTEPH. Nine of 31 (29%) white patients with CTEPH versus 10 of 129 (7.8%) patients with non-CTEPH were heterozygous for factor V Leiden (FVL; P = 0.001). Contrary to other studies, antiphospholipid antibodies (APA) were not increased. Elevated factor VIII (FVIII) and von Willebrand factor (VWF; >1.5 U/ml) were common in CTEPH and non-CTEPH, although significantly higher (P = 0.01 for FVIII and 0.009 for VWF) in CTEPH versus non-CTEPH. There was no correlation between FVIII-VWF and fibrinogen levels in the CTEPH group (P = 0.84 for FVIII and 0.49 for VWF) but a strong correlation between FVIII-VWF and fibrinogen in the non-CTEPH (P < 0.0001). There was no association between FVIII-VWF and WHO functional status in the CTEPH group although there was a strong correlation (P < 0.001) between the two parameters in the non-CTEPH group. For equivalent WHO functional class, FVIII levels were significantly higher (P = 0.007) in the CTEPH group. We have found no association between FVIII-VWF levels and oxygen saturation in both groups of patients. The results indicate different pathophysiologies for CTEPH and non-CTEPH. The elevation of FVIII and increased incidence of FVL gene polymorphisms in the CTEPH group support a primary role of thrombosis in aetiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182352     DOI: 10.1097/MBC.0b013e328331e664

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  12 in total

1.  Prevalence of antiphospholipid antibodies among patients with chronic thromboembolic pulmonary hypertension.

Authors:  Andrea Cervi; James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2019-04-01       Impact factor: 3.397

2.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 3.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 4.  Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Krittika Teerapuncharoen; Remzi Bag
Journal:  Lung       Date:  2022-05-29       Impact factor: 2.584

Review 5.  Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.

Authors:  David S Poch; William R Auger
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 7.  Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis.

Authors:  Ayesha Zia; Joy Russell; Ravi Sarode; Surendranath R Veeram; Shellie Josephs; Kendra Malone; Song Zhang; Janna Journeycake
Journal:  Thromb Res       Date:  2017-10-07       Impact factor: 3.944

Review 8.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

9.  Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1 Year After First Episode of Acute Pulmonary Embolism: A Cohort Study.

Authors:  Farid Rashidi; Rezayat Parvizi; Eisa Bilejani; Babak Mahmoodian; Fatemeh Rahimi; Ata Koohi
Journal:  Lung       Date:  2020-01-02       Impact factor: 2.584

10.  Reply to comments and questions of Dr. Correale et al. about our review concerning CTEPH.

Authors:  Bastiaan E Schölzel; Repke J Snijder; Johannes J Mager; Hendrik W van Es; Herbert W M Plokker; Herre J Reesink; Wim J Morshuis; Martijn C Post
Journal:  Neth Heart J       Date:  2015-03       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.